Search
AZD7442
go.drugbank.com/drugs/DB15787InvestigationalAZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]
Categories: Experimental Unapproved Treatments for COVID-19Rheinanthrone
go.drugbank.com/drugs/DB13175ExperimentalRheinanthrone is the active metabolite of senna glycoside [DB11365] known for its laxative effect [A19235]. It is commonly produced by plants of the Rheum species [L772].
GC012F
go.drugbank.com/drugs/DB22406InvestigationalGC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).
Dabigatran
go.drugbank.com/drugs/DB14726ApprovedInvestigationalDabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
Categories: Factor Xa Inhibitors, Direct factor Xa inhibitorsAfelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Niflumic acid
go.drugbank.com/drugs/DB04552InvestigationalNiflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UseACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington … ACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases.
Cilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Categories: Drugs for Functional Gastrointestinal DisordersEVT 201
go.drugbank.com/drugs/DB05721InvestigationalEVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.